文献速递神经肿瘤

全基因组CRISPR-Cas9筛选揭示胶质瘤CDK4/6抑制剂反应的分子调节因子

Molecular modulators of cyclin-dependent kinase 4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening.
PubMed 文献 · Neuro Oncol · 2026-01-01

本研究通过全基因组CRISPR-Cas9筛选在人胶质瘤细胞系和干细胞样细胞中寻找CDK4/6抑制剂反应的调节因子,发现AMBRA1缺失和CCNE1功能获得降低敏感性,而CHEK1或FAM122A破坏与CDK4/6抑制产生合成致死。联合抑制CHK1和CDK4/6在体外、离体和体内均显示协同抗胶质瘤活性。

要点

  • AMBRA1缺失和CCNE1功能获得降低胶质瘤细胞对CDK4/6抑制的敏感性。
  • CHEK1或FAM122A破坏与CDK4/6抑制联合产生合成致死效应。
  • CHK1与CDK4/6联合抑制在体内外均显示协同抗胶质瘤活性。

核心结论

  • AMBRA1、CCNE1、CHEK1和FAM122A是实验性胶质瘤中CDK4/6抑制反应的潜在分子调节因子。
  • 联合靶向CHK1和CDK4/6为胶质母细胞瘤提供了生物学依据。

研究设计与样本

  • 在人胶质瘤细胞系和干细胞样细胞(LN229、LN18、LNZ308、T98G和GS-9)中进行全基因组CRISPR-Cas9筛选,采用敲除(Brunello文库)和激活(Calabrese文库)策略。
  • 对候选基因进行体外、离体(原代培养)遗传和药理学验证,并在体内研究一种功能指导的联合治疗。

主要发现

  • AMBRA1缺失和CCNE1功能获得降低胶质瘤细胞对CDK4/6抑制的敏感性。
  • CHEK1或FAM122A破坏与CDK4/6抑制联合导致合成致死。
  • AMBRA1缺陷的胶质瘤细胞对CHK1抑制敏感性增加。
  • CHK1和CDK4/6联合抑制在体外、离体和体内产生协同抗胶质瘤活性。

临床怎么用

  • 研究提示CDK4/6抑制剂联合CHK1抑制剂可能成为胶质母细胞瘤的潜在治疗策略。
  • AMBRA1缺陷可能作为CHK1抑制的上下文特异性脆弱性标志。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma harbors frequent alterations in the retinoblastoma pathway, providing a genetic rationale for therapeutic targeting with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The NOA-20 trial did not reveal a progression-free survival benefit of CDK4/6 inhibition plus radiation therapy in newly diagnosed, O6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma. In fact, CDK4/6 inhibitor monotherapy has not demonstrated efficacy in solid tumors. We aimed at discovering response modulators to CDK4/6 inhibition, paving the way for rational combination therapies. METHODS: We conducted genome-wide CRISPR-Cas9 screens in human glioma cell lines and stem-like cells (LN229, LN18, LNZ308, T98G, and GS-9) under CDK4/6 inhibition, employing knockout (Brunello library) and activation strategies (Calabrese library), followed by genetic and pharmacological validation of selected candidate genes in vitro and ex vivo (primary cultures) as well as the investigation of 1 functionally instructed combination therapy in vivo. RESULTS: Loss of AMBRA1 and gain of function of CCNE1 reduced sensitivity to CDK4/6 inhibition in glioma cells, whereas disruption of checkpoint kinase 1 (CHEK1) or FAM122A resulted in synthetic lethality in combination with CDK4/6 inhibition. AMBRA1-deficient glioma cells exhibited increased sensitivity to CHK1 inhibition, revealing a context-specific vulnerability. Combined inhibition of CHK1 and CDK4/6 led to synergistic antiglioma activity in vitro, ex vivo, and in vivo. CONCLUSIONS: Our data identify AMBRA1, CCNE1, CHEK1, and FAM122A as potential molecular modifiers of CDK4/6 inhibition response in experimental glioma and provide a biological rationale for combinatorial targeting with CDK4/6 inhibition in glioblastoma. This study explores treatment strategies for glioblastoma, an aggressive type of brain cancer. Drugs that inhibit cyclin-dependent kinase 4/6 (CDK4/6) have shown little benefit when used alone. In this study, we searched for genetic factors that influence how tumor cells respond to these drugs. Using advanced gene-editing techniques, we identified several genes that alter sensitivity to CDK4/6 inhibition. Importantly, combining CDK4/6 inhibitors with checkpoint kinase 1 inhibitors showed much stronger antitumor effects in laboratory and animal models. These findings provide insights into how combination therapies could be used effectively, potentially leading to improved and more personalized treatment options for patients with glioblastoma in the future.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Surender S, Haeusser LA, Kuhlburger L, et al. Molecular modulators of cyclin-dependent kinase 4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening. Neuro Oncol. 2026. PMID: 42083788. doi:10.1093/neuonc/noag093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。